Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Schindler

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody diseaseItay Lotan, John J Chen, Yael Hacohen, et al.
JAMA Neurology|December 23, 2024
Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum DisorderSu-Hyun Kim, Ana Beatriz Ayroza Galvão Ribeiro Gomes, Patrick Schindler, et al.
European Journal of Neurology|February 4, 2026
Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4-IgG+ NMOSD Treated With Rituximab-A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group (NEMOS)Daniel Engels, Mariella Herfurth, Joachim Havla, et al.
BMJ Neurology Open|October 24, 2025
Dyadic Coping of NMOSD and MOGAD patients and their partners: a sociological and psychological examination of strategies (CoMMOnsense-Study)Anna Walz, Daria Tkachenko, Martin W Hümmert, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 31, 2024
Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)Sarah Passoke, Carlotta Stern, Vivien Häußler, et al.
Neurology|July 2, 2026
Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort StudyDaniel Engels, Patrick Schindler, Joachim Havla, et al.
ACS Medicinal Chemistry Letters|December 21, 2019
Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload OptimizationAlexei S Karpov, Cristina M Nieto-Oberhuber, Tinya Abrams, et al.
Science Translational Medicine|March 27, 2024
Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectoriesCatharina C Gross, Andreas Schulte-Mecklenbeck, Olga V Steinberg, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 4, 2024
Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacksCarolin Schwake, Theodoros Ladopoulos, Vivien Häußler, et al.
JAMA Neurology|August 7, 2023
Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System DemyelinationAna Beatriz Ayroza Galvão Ribeiro Gomes, Laila Kulsvehagen, Patrick Lipps, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody diseaseItay Lotan, John J Chen, Yael Hacohen, et al.
JAMA Neurology|December 23, 2024
Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum DisorderSu-Hyun Kim, Ana Beatriz Ayroza Galvão Ribeiro Gomes, Patrick Schindler, et al.
European Journal of Neurology|February 4, 2026
Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4-IgG+ NMOSD Treated With Rituximab-A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group (NEMOS)Daniel Engels, Mariella Herfurth, Joachim Havla, et al.
BMJ Neurology Open|October 24, 2025
Dyadic Coping of NMOSD and MOGAD patients and their partners: a sociological and psychological examination of strategies (CoMMOnsense-Study)Anna Walz, Daria Tkachenko, Martin W Hümmert, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 31, 2024
Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)Sarah Passoke, Carlotta Stern, Vivien Häußler, et al.
Neurology|July 2, 2026
Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort StudyDaniel Engels, Patrick Schindler, Joachim Havla, et al.
ACS Medicinal Chemistry Letters|December 21, 2019
Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload OptimizationAlexei S Karpov, Cristina M Nieto-Oberhuber, Tinya Abrams, et al.
Science Translational Medicine|March 27, 2024
Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectoriesCatharina C Gross, Andreas Schulte-Mecklenbeck, Olga V Steinberg, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 4, 2024
Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacksCarolin Schwake, Theodoros Ladopoulos, Vivien Häußler, et al.
JAMA Neurology|August 7, 2023
Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System DemyelinationAna Beatriz Ayroza Galvão Ribeiro Gomes, Laila Kulsvehagen, Patrick Lipps, et al.
Pageof 6